Načítá se...
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Class I histone deacetylases (HDACs) are promising targets for epigenetic therapies for a range of diseases such as cancers, inflammations, infections and neurological diseases. Although six HDAC inhibitors are now licensed for clinical treatments, they are all pan-inhibitors with little or no HDAC...
Uloženo v:
| Vydáno v: | Int J Mol Sci |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7700698/ https://ncbi.nlm.nih.gov/pubmed/33266366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21228828 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|